![]() ![]() Additionally, patients often experience haemolysis, or rapid breakdown, of their red blood cells, which can lead to anaemia, damage to vital organs, and a reduced lifespan. The irregularly shaped and sticky red blood cells produced by the disease can obstruct small blood vessels, causing recurring painful attacks. In sickle cell disease, however, this function is impaired, leading to a range of potential health consequences. The red blood cells contain haemoglobin, which plays a crucial role in transporting oxygen throughout the body. One such drug, Panobinostat, has been singled out for further investigation. 1Īccording to Abdullah Kutlar, MD, who serves as the director of the Center for Blood Disorders at the Medical College of Georgia and Augusta University Health, these drugs, referred to as HDAC inhibitors, have shown initial evidence of reactivating the gene responsible for producing foetal haemoglobin, which cannot undergo sickling after birth. Foetal haemoglobin (HbF) is the predominant type of haemoglobin (Hb) in foetal life and remains so until just before birth when its production is turned down while the production of adult Hb is turned up. Results of the Multicenter Study of Hydroxyurea in Sickle Cell Anaemia published in the Journal of the American Medical Associationin 2003, indicated that the use of hydroxyurea, the only drug approved at the time, reduced mortality as it reduced pain crises and increased foetal haemoglobin. ![]()
0 Comments
Leave a Reply. |